202 related articles for article (PubMed ID: 36319945)
21. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
[TBL] [Abstract][Full Text] [Related]
22. Chronic cough: more than just a persistent cough: a systematic literature review to understand the impact of chronic cough on quality of life.
Bali V; Adriano A; Byrne A; Akers KG; Frederickson A; Schelfhout J
Qual Life Res; 2024 Apr; 33(4):903-916. PubMed ID: 38153616
[TBL] [Abstract][Full Text] [Related]
23. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.
McGarvey L; Smith JA; Morice A; Birring SS; Chung KF; Dicpinigaitis PV; Niimi A; Benninger MS; Sher M; Matsunaga Y; Miyazaki S; Machida M; Ishihara H; Mahmood A; Gomez JC
Lung; 2023 Feb; 201(1):25-35. PubMed ID: 36512069
[TBL] [Abstract][Full Text] [Related]
24. Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study.
Zhang M; Morice AH; Si F; Zhang L; Chen Q; Wang S; Zhu Y; Xu X; Yu L; Qiu Z
Ther Adv Respir Dis; 2023; 17():17534666231167716. PubMed ID: 37078383
[TBL] [Abstract][Full Text] [Related]
25. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis.
Monreal E; Ruiz PD; San Román IL; Rodríguez-Antigüedad A; Moya-Molina MÁ; Álvarez A; García-Arcelay E; Maurino J; Shepherd J; Cabrera ÁP; Villar LM
Front Public Health; 2024; 12():1397845. PubMed ID: 38711771
[TBL] [Abstract][Full Text] [Related]
26. [Chronic cough].
Kardos P
Pneumologie; 2023 Aug; 77(8):574-585. PubMed ID: 37619576
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR
Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.
Gibson P; Wang G; McGarvey L; Vertigan AE; Altman KW; Birring SS;
Chest; 2016 Jan; 149(1):27-44. PubMed ID: 26426314
[TBL] [Abstract][Full Text] [Related]
29. Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
Muccino DR; Morice AH; Birring SS; Dicpinigaitis PV; Pavord ID; Assaid C; Kleijn HJ; Hussain A; La Rosa C; McGarvey L; Smith JA
ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33263037
[TBL] [Abstract][Full Text] [Related]
30. Burden of refractory and unexplained chronic cough on patients' lives: a cohort study.
Puente-Maestu L; Dávila I; Quirce S; Crespo-Lessmann A; Martínez-Moragón E; Sola J; Nieto ML; González-Barcala FJ; Cea-Calvo L; Sánchez-Jareño M; Rivas-Pardinas C; Domingo C
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37753282
[TBL] [Abstract][Full Text] [Related]
31. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Muccino D; Green S
Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
[TBL] [Abstract][Full Text] [Related]
32. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
33. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study.
Wahlster P; Goetghebeur M; Schaller S; Kriza C; Kolominsky-Rabas P;
Health Res Policy Syst; 2015 Apr; 13():24. PubMed ID: 25928535
[TBL] [Abstract][Full Text] [Related]
34. [New ICD-10 code for refractory and unexplained chronic cough].
Millqvist E; Janson C; Bredin C
Lakartidningen; 2023 Mar; 120():. PubMed ID: 36942650
[TBL] [Abstract][Full Text] [Related]
35. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
[TBL] [Abstract][Full Text] [Related]
36. Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel.
Kum E; Guyatt GH; Munoz C; Beaudin S; Li SA; Abdulqawi R; Badri H; Boulet LP; Chen R; Dicpinigaitis P; Dupont L; Field SK; French CL; Gibson PG; Irwin RS; Marsden P; McGarvey L; Smith JA; Song WJ; O'Byrne PM; Satia I
ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35295233
[TBL] [Abstract][Full Text] [Related]
37. A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; Casado MÁ; Trillo JL; Ruiz-Moreno JM; Martínez-Sesmero JM; Peralta G; Poveda JL; Ortiz P; Ignacio E; Zarranz-Ventura J; Udaondo P; Mur C; Álvarez E; Cervera E; Martínez M; Llorente I; Zulueta J; Rodríguez-Maqueda M; García-Layana A; Martínez-Olmos J
Pharmacoecon Open; 2020 Dec; 4(4):615-624. PubMed ID: 32100249
[TBL] [Abstract][Full Text] [Related]
38. Is laryngeal hypersensitivity the basis of unexplained or refractory chronic cough?
Sundar KM; Stark AC; Hu N; Barkmeier-Kraemer J
ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33816599
[TBL] [Abstract][Full Text] [Related]
39. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
40. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
